Cortex Pharmaceuticals, Inc.
What Are Ampakines and How Can They Help Treat Parkinson’s
Topic: Parkinson’s Disease
Cortex Receives Funding from The Michael J. Fox Foundation to Discover Drug Candidates for Parkinson's Disease
Cortex Pharmaceuticals, Inc. (OTCBB: CORX) announced that it has been awarded a grant by The Michael J.
Cortex to Hold Annual Shareholder Meeting on May 19 at Marriott Newport Beach Hotel in Newport Beach, CA
Cortex Pharmaceuticals, Inc.
Huntington's Therapeutics Reviewed by NeuroInvestment
NI Research has released the April issue of NeuroInvestment.
O.C. Firm’s Drug Sale Worth Up To $25 million
Cortex Pharmaceuticals Inc. in Irvine has sold for $10 million certain of its drug compounds.
Cortex Reports Fourth Quarter and Year End Operating Results
Cortex Pharmaceuticals, Inc.
Cortex Sells Selected AMPAKINE Compounds and Rights to Respiratory Depression Indication to Biovail
Purchase Price of $10 Million and up to $15 Million Clinical Development Milestones
Cortex Pharmaceuticals Inc.
Cortex Pharmaceuticals is a neuroscience company focused on the discovery, development and commercialization of novel drug therapies for the treatment of neurological and psychiatric disorders.
